Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
doi: 10.1016/j.jep.2024.119231 2 NiXWangQNingYLiuJSuQLvSet al
Patients should be advised to: Start with the lowest dose and increase slowly Eat smaller, more frequent meals Avoid high-fat foods Stay well-hydrated Safety monitoring should include vigilance for: Pancreatitis symptoms (severe persistent abdominal pain) discontinue immediately if suspected Gallbladder disease increased risk with rapid weight loss Hypoglycaemia particularly when combined with insulin or sulphonylureas Renal function deterioration especially with dehydration from gastrointestinal effects Diabetic retinopathy monitor in patients with pre-existing retinopathy, particularly with semaglutide Suspected adverse reactions should be reported via the MHRA Yellow Card scheme
By subscribing, you accept our Terms & Privacy Policy.
If a patient replies with a regulatory question, the second-touch response can be more detailed
US$ 29.85
US$ 27.25
US$ 24.22
US$ 26.92
US$ 28.25
US$ 28.30
US$ 27.75
US$ 29.69
US$ 21.07
US$ 26.12
